MK-0159 Chemical Structure oral CD38 inhibitor - Mitobridge (an Astellas Company), Cambridge, MA

oral CD38 inhibitor

in vivo efficacy in a murine model of cardiac I/R

from the previously disclosed inhibitor CD38i

J. Med. Chem.

Mitobridge (an Astellas Company), Cambridge, MA

Context. MK-0159 (Mitobridge) is an oral CD38 inhibitor being developed for cardiovascular diseases. Due to its NADP+ depleting activity, which has implications for calcium homeostasis, the cell surface marker…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.